SnagRx Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8.3/10
Best for: semaglutide at $99/month, 48% under the register median
SnagRx's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
then $99/mo ongoing
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
SnagRx runs a launch discount that puts compounded semaglutide at $99/mo and compounded tirzepatide at $149/mo, with pricing described as flat for life at the same price every dose. The cash-pay service comes from Modern Metabolic Medicine, Inc. and ships to the door in 1-2 days. No insurance and no membership; the telehealth visit and shipping are included.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to SnagRx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
SnagRx at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $69/mo ($99/mo is the 1-month billing cycle on snagrx.com/semaglutide, re-verified live 2026-08-11: 1-month $99, 3-month $89,...)
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How SnagRx scores
Six columns, each one computed from something SnagRx has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
9.7/10$99/month is 48% below the register median of $189 for compounded semaglutide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
6.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on SnagRx
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with SnagRx involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1SnagRx publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3SnagRx does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: semaglutide $99, tirzepatide $149. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether SnagRx serves your state cannot be confirmed from its site.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
SnagRx support, as documented
- Phone
- (469) 459-3723
- hello@snagrx.com
GLP-1 medications SnagRx offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
$99/mo is the 1-month billing cycle on snagrx.com/semaglutide, re-verified live 2026-08-11: 1-month $99, 3-month $89, 6-month $79, 12-month $69, same price at every dose. The $299 shown struck through on the homepage is a permanent anchor, not a rate anyone pays - it was already struck through on 2026-06-19 and still is, beside a countdown reading 00:00:00:00. Budget from $99; $69 needs a full year paid up front.
$149/mo is the 1-month billing cycle on snagrx.com/semaglutide, re-verified live 2026-08-11: 1 month $149, 3 months $139, 6 months $129, 12 months $119, same price at every dose. The $399 shown struck through on the homepage is a permanent anchor, not a rate anyone pays. Budget from $149; $119 needs a full year paid up front.
Check the price yourself before you pay
Every figure here was read off SnagRx's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $149 a month, 44% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What SnagRx charges
SnagRx advertises $69. That buys the first month. The standing rate is $99/month, and that is the one worth doing arithmetic on, because the introductory figure applies once.
- Compounded semaglutide — $69 first month, then $99/month
- Compounded tirzepatide — $119 first month, then $149/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so SnagRx is genuinely under the middle rather than merely advertising that it is.
TRYM Health dispenses semaglutide and tirzepatide from $96/month, which makes it the honest comparison to run before committing here.
What SnagRx dispenses
SnagRx prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
What we could verify
SnagRx publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You would be choosing on the advertised figure. The introductory month is real, but it is not what you will be paying in month three.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want the price to stop moving as your dose climbs
- you want a cheap way to find out whether the medication suits you before committing
Our read
SnagRx is a cheap way to start and an ordinary way to continue. Use the $69 month for what it is good for — establishing whether the medication works for you — and re-run the numbers against $99/month before you let it renew twice.
The Bottom Line
SnagRx's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay SnagRx
Starting at $69/month. Check today's price, then book the free consultation.
Where SnagRx is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this SnagRx review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See SnagRx's current pricing
Plans start at $69/month. The free consultation is where you learn whether you qualify, and what it costs today.